Trial Profile
A Phase III, Exercise Capacity Study Evaluating Ralinepag for the Treatment of Pulmonary Arterial Hypertension (PAH)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs Ralinepag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms ADVANCE ENDURANCE 304
- 22 May 2019 Trial design presented at the 115th International Conference of the American Thoracic Society
- 14 Aug 2018 New trial record
- 06 Aug 2018 According to an Arena Pharmaceuticals media release, the company expect to initiate this trial in Q1:19.